Point72 Hong Kong Ltd bought a new stake in shares of Genmab A/S (NASDAQ:GMAB - Free Report) in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund bought 43,671 shares of the company's stock, valued at approximately $911,000.
A number of other institutional investors and hedge funds also recently modified their holdings of GMAB. EverSource Wealth Advisors LLC grew its position in shares of Genmab A/S by 295.3% during the 4th quarter. EverSource Wealth Advisors LLC now owns 1,257 shares of the company's stock valued at $26,000 after buying an additional 939 shares during the last quarter. Lindbrook Capital LLC boosted its stake in Genmab A/S by 105.4% in the fourth quarter. Lindbrook Capital LLC now owns 1,851 shares of the company's stock valued at $39,000 after acquiring an additional 950 shares during the period. Barclays PLC boosted its stake in Genmab A/S by 1,072.8% in the fourth quarter. Barclays PLC now owns 2,498 shares of the company's stock valued at $52,000 after acquiring an additional 2,285 shares during the period. Cromwell Holdings LLC grew its holdings in shares of Genmab A/S by 656.8% during the fourth quarter. Cromwell Holdings LLC now owns 2,876 shares of the company's stock valued at $60,000 after purchasing an additional 2,496 shares during the last quarter. Finally, R Squared Ltd acquired a new stake in shares of Genmab A/S during the 4th quarter worth approximately $93,000. 7.07% of the stock is owned by institutional investors and hedge funds.
Wall Street Analyst Weigh In
A number of research analysts recently issued reports on the company. Truist Financial reduced their price objective on Genmab A/S from $50.00 to $45.00 and set a "buy" rating for the company in a research report on Tuesday, March 11th. William Blair upgraded Genmab A/S from a "market perform" rating to an "outperform" rating in a research note on Tuesday, March 11th. HC Wainwright reissued a "buy" rating and set a $37.00 price target (down previously from $50.00) on shares of Genmab A/S in a report on Wednesday, April 9th. Sanford C. Bernstein lowered shares of Genmab A/S from a "market perform" rating to an "underperform" rating in a research report on Tuesday, April 1st. Finally, Leerink Partners raised shares of Genmab A/S from a "market perform" rating to an "outperform" rating and set a $27.00 price objective on the stock in a report on Thursday, February 13th. One analyst has rated the stock with a sell rating, three have issued a hold rating, eight have assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus target price of $39.17.
Check Out Our Latest Report on Genmab A/S
Genmab A/S Stock Up 1.1%
Genmab A/S stock traded up $0.23 during trading hours on Wednesday, hitting $20.56. 795,913 shares of the company traded hands, compared to its average volume of 1,113,840. Genmab A/S has a 1-year low of $17.24 and a 1-year high of $30.06. The firm has a market cap of $13.18 billion, a P/E ratio of 11.82, a P/E/G ratio of 2.65 and a beta of 1.04. The firm's 50-day simple moving average is $19.75 and its two-hundred day simple moving average is $20.72.
Genmab A/S (NASDAQ:GMAB - Get Free Report) last posted its quarterly earnings data on Thursday, May 8th. The company reported $0.31 EPS for the quarter, beating analysts' consensus estimates of $0.23 by $0.08. The business had revenue of $715.00 million for the quarter, compared to analyst estimates of $5.17 billion. Genmab A/S had a net margin of 36.30% and a return on equity of 16.78%. On average, equities research analysts predict that Genmab A/S will post 1.45 earnings per share for the current year.
Genmab A/S Company Profile
(
Free Report)
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.
Read More
Before you consider Genmab A/S, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Genmab A/S wasn't on the list.
While Genmab A/S currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
